In this review, we discuss current thinking in relation to available guidelines for the care of preschool-aged children with recurrent wheezing, while highlighting the gaps in our knowledge and discussing changes that could occur over the next 5 years.
INTRODUCTION
Asthma is an increasingly prevalent chronic disease among children worldwide and is associated with significant morbidity, mortality and economic burden. Much research effort has focused on management strategies for established asthma, yet there are significant knowledge gaps in our understanding of young children with recurrent wheezing and progression to asthma. At the 2016 AAAAI Life Spectrum of Asthma meeting, workshop groups were asked to discuss a case of an 18-month-old child with recurrent wheezing. This case presented a unique opportunity to assimilate current thinking in relation to available guidelines with significant changes that could occur over the next 5 years.
CASE PRESENTATION
An 18-month-old male child has experienced four episodes of wheezing, some severe enough to require evaluation in an urgent care clinic and a course of oral corticosteroids. The child has a positive Asthma Predictive Index (API). How would you counsel the parents who want to prevent their child from developing asthma and/or more severe symptoms?
The asthma predictive index
Originally developed from the Tucson Children's Respiratory Study, the API is a well-validated tool that uses major and minor criteria to predict which children with early wheezing will go on to have asthma [2] [3] [4] [5] . The presence of recurrent wheezing in the first 3 years of life and one major or two minor clinical criteria is considered positive and associated with an odds ratio of 9.8 (5.6-17.2) for asthma at age 6 years (Table 1) [5] [6] [7] . Modified versions of the API have been developed and validated and include allergen sensitization as a criterion that increases risk of asthma by school-age [6] [7] [8] .
The Tucson Children's Respiratory Study found that young children with persistent wheezing demonstrated reduced maximal expiratory flow at age 6 compared with children who never wheezed. A follow-up of this study found that this pulmonary deficit persisted at age 16, suggesting that the insults resulting in reduced lung function occur in the first few years of life [9] . The appeal of the API lies in its potential to capture high-risk children during this critical window before development of abnormal lung function so that targeted treatment can be initiated. The API has high specificity and negative predictive value but low sensitivity and positive predictive value, and therefore it cannot be used to definitively rule out future asthma development or predict asthma severity [3] [4] [5] 10] . Despite its limitations, the API is a well-validated and easily applied screening tool to evaluate asthma risk in young wheezing children.
Allergen-specific immunoglobulin E
Allergic sensitization appears to be a key player in asthma inception [11, 12] , particularly aeroallergen sensitization early in life [13, 14] . This relationship appears to be more complex than simply the presence or absence of atopy, with age at onset and type and number of aeroallergens playing an important role in asthma risk [15] . Multiple studies [15] [16] [17] [18] [19] have shown a significant relationship between sensitization to multiple allergens in early life and persistent wheezing, reduced lung function and hospital admissions for asthma. In addition, allergen sensitization appears to enhance the risk of rhinovirus-induced wheezing, and the combination of early sensitization and viral infection increases asthma risk [20] [21] [22] . The National Asthma Education and Prevention Program (NAEPP) suggests that allergy testing be considered in young children
KEY POINTS
Insults resulting in reduced lung function occur in the first few years of life, so primary preventive strategies should be targeted toward very young children.
The API and biomarkers such as specific IgE, blood eosinophils and FeNO are useful tools to estimate asthma risk in young wheezing children.
Daily ICS use in young wheezing children does not modify progression to asthma or prevent decline in lung function but does reduce impairment and exacerbations particularly in children with elevated blood eosinophils and/or aeroallergen sensitization.
Allergen immunotherapy and monoclonal antibodies targeting T H 2 inflammation may represent strategies for primary prevention of allergic asthma, but efficacy and safety studies in young children are needed. 
Peripheral blood eosinophils
Persistent eosinophilia in early childhood is associated with asthma later in life [24] , and blood eosinophils at least 4% are included as a minor criterion in the API [5] . The Tucson Children's Respiratory Study found a linear relationship between blood eosinophils and the presence of asthma across the ages of 9 months-11 years, independently of atopy, with the most chronic asthma found in the group with peripheral eosinophil counts greater than 5% [24] . Similarly, children under 2 with bronchiolitis and peripheral eosinophil count of more than 0.45 Â10 9 cells/l were at increased risk of asthma at ages 7 and 12 years [25, 26] . The Individualized Therapy for Asthma in Toddlers (INFANT) study showed that children 12-59 months with blood eosinophils at least 300/ml and/or sensitization to at least one aeroallergen showed the most significant improvement in asthma control days and frequency of exacerbations when treated with daily inhaled corticosteroids (ICSs) [ ]. FeNO level at 4 years of age is higher in persistent wheezers compared with transient wheezers and those who have never wheezed [34] , and higher FeNO at age 4 is associated with greater risk of asthma at age 7 [14, 35] . These findings have been replicated in several similar studies [36] [37] [38] [39] . Moreover, FeNO also appears to predict responsiveness to inhaled corticosteroids [40 & ,41] , with higher FeNO predicting greater improvement in symptoms, lung function and inflammatory markers in children with asthma treated with ICS compared with montelukast [28, 42] . The use of FeNO in clinical practice is increasing and should be considered for establishing the endotype of airway disease and predicting steroid-responsiveness.
WHAT INTERVENTIONS, IF ANY, CAN IMPACT THE RISK FOR AND SEVERITY OF ASTHMA?
Guidelines for management of young wheezing children are lacking. In this section, we will discuss evidence-based treatment options as well as potential primary preventive strategies.
Inhaled corticosteroids
According to the NAEPP, ICSs are the preferred longterm controller therapy in children regardless of age to improve symptom control and quality of life [23] . Despite this recommendation, there is continuing debate in the field regarding the usefulness of corticosteroids in wheezing preschool-aged children. Some of this debate has arisen from studies [43, 44] showing a lack of efficacy of oral corticosteroids for acute wheezing episodes in this age group. However, certain groups of wheezing children may be more responsive to corticosteroids than others, as seen in the INFANT study [27 && ] as well as others showing greater response to ICS in children with higher FeNO and peripheral eosinophilia [28, 42] . Although effective for reducing impairment and exacerbations, ICSs do not appear to impact loss of lung function over time. The Childhood Asthma Management Program study [45] found that daily inhaled budesonide improved asthma control in 5-12-year-old children but did not impact the degree of change in lung function over time when compared with placebo. The Prevention of Early Asthma in Kids trial found that daily ICS treatment in preschool-aged children with positive modified API was associated with fewer symptoms and exacerbations, but the effect was lost upon discontinuation of ICS, suggesting a lack of disease-modifying effects [6, 7] (Fig. 1) .
Most preschool-aged wheezing children experience little or no impairment between exacerbations, which tend to be associated with viral respiratory infections. Many clinicians have begun the practice of using ICS only during acute wheezing episodes or seasonally during fall and winter seasons when viral illnesses are most likely to occur. The Maintenance vs. Intermittent Inhaled Steroids in Wheezing Toddlers trial compared high-dose ICS at the first signs of viral respiratory illness with daily ICS treatment in preschool-aged children with positive API but low degree of impairment (not meeting criteria for step 2 asthma therapy) [23, 46] . The authors reported no difference between the groups in frequency of severe exacerbations.
Although ICS is not effective for primary prevention of asthma, the evidence suggests some benefit in preschool-aged children with recurrent wheezing episodes. Those children who demonstrate elevated blood eosinophils and/or aeroallergen sensitization may benefit the greatest from ICS treatment. More study is needed to better characterize ICS responders and nonresponders to allow development of additional treatment options.
Leukotriene receptor antagonists
Montelukast is approved for children as young as 1 year of age and is recommended as an alternative to ICS when initiating controller therapy for asthma [23] . Efficacy studies of montelukast in young children demonstrate benefit particularly in the setting of viral-induced wheezing. The Prevention of Viral Induced Asthma study of children 2-5 years of age treated with montelukast daily for 12 months demonstrated reduction in the frequency of viralinduced exacerbations of asthma compared with placebo [47] . Another study [48] demonstrated reduced symptoms, need for rescue medications and oral corticosteroids in 2-5-year-old children with asthma who received montelukast daily for 12 weeks. Children with favorable response to montelukast tend to be of younger age and shorter disease duration with lower FeNO, peripheral eosinophilia and serum IgE levels according to one study [28] . The recently published INFANT trial found that many participants responded best to daily LTRA compared with daily or as-needed ICS but was unable to identify characteristics or biomarkers that predicted this response [27 && ]. Montelukast may be an appropriate first-line therapy for a selected population of preschool-aged wheezing children, but further study is needed to identify those most likely to have a favorable response.
Macrolides
Antibiotics are commonly prescribed during outpatient visits for wheezing, with macrolides being the most common [49] . Macrolides are frequently prescribed for cystic fibrosis and chronic obstructive pulmonary disease because of their anti-inflammatory properties and may have a role in treatment of recurrent wheezing and asthma as well. Bacharier et al. [50 && ] conducted a randomized, doubleblinded trial of preschool children, half of whom had a positive modified API, using early administration of azithromycin 12 mg/kg for 5 days or placebo at the onset of respiratory illness and found a reduction in episodes of severe lower airway respiratory illness in the azithromycin group compared with placebo. Subgroup analyses found no significant effect of API on response to azithromycin. In an unselected Danish birth cohort, COPSAC 2010, a 3-day course of 10 mg/kg azithromycin after the onset of respiratory illness resulted in significant shortening of episodes of asthma-like symptoms compared with placebo in children ages 1-3 [51 & ]. In a randomized placebo-controlled study [52 & ] of infants hospitalized with respiratory syncytial virus (RSV) bronchiolitis, azithromycin treatment during the episode prolonged time to the next wheezing episode and resulted in fewer symptomatic days over the subsequent year. Macrolides are thought to be more effective in noneosinophilic airway inflammation, particularly neutrophilic inflammation associated with some types of asthma [53, 54] . Although not part of the current asthma management guidelines, macrolides could be considered for use during respiratory illness in preschool-aged children with wheezing to prevent progression to more severe symptoms.
Allergen-specific immunotherapy
Allergen-specific subcutaneous immunotherapy (SCIT) has been shown to effectively reduce asthma symptoms, corticosteroid requirement and improve quality of life, and may be one of the only available treatment options, apart from avoidance of tobacco smoke, for primary prevention of asthma in children [55] [56] [57] . The European multicenter Preventive Allergy Treatment study randomized children 6-14 years with allergic rhinoconjunctivitis but without asthma who were sensitized to birch and/or grass pollen to SCIT containing birch and/or grass pollen or to an open control group for 3 years. Individuals who received SCIT were less likely to have asthma at 2 and 7 years after study completion than the control group [58] [59] [60] . Sublingual immunotherapy (SLIT) trials have shown less consistent benefit in treatment of allergic asthma in older children, and a recent Cochrane review concluded that further research is needed to determine if SLIT is an effective treatment for asthma [61] . Clinical trials in preschool-aged children are needed to confirm the efficacy and safety of allergen-specific immunotherapy for asthma prevention.
Anti-IgE therapy
Omalizumab is currently approved for adults and children 6 years and older with persistent asthma not well controlled on ICS and with sensitization to perennial allergen(s). In children and adolescents with allergic asthma, omalizumab resulted in decreased ICS dosage [62, 63] , frequency of asthma exacerbations [62-64,65 & ], reduced rescue medication requirement [62] and decreased unscheduled healthcare visits [62] and hospitalizations [65 & ]. Recently, there has been increasing interest in the use of anti-IgE therapies for primary prevention of asthma, presumably by preventing the cascade of inflammatory events early in life that lead to asthma. Studies in adults have suggested that frequent exacerbations are associated with more rapid decline in lung function over time [66] , potentially because of repetitive injury leading to airway remodeling. By preventing exacerbations, omalizumab may have the potential to prevent irrecoverable loss of lung function, but to date this has not been studied. Trials of omalizumab in preschool-aged children are likely on the horizon as a potential treatment for primary asthma prevention.
Other anti-T H 2 therapies
Additional biologics aimed at T helper cell type 2 (T H 2) cytokines interleukin (IL) 4, 5 and 13 are currently under investigation for the treatment of T H 2-high asthma. Anti-IL-5 monoclonal antibody (mAb) therapy has been shown to reduce exacerbations in adults with eosinophilic asthma [67, 68] , and clinical trials in children are ongoing. Similarly, anti-IL-4Ra therapy appears to reduce the frequency of asthma exacerbations and improves lung function in adults with eosinophilic asthma [69] , but no studies have been published in children. Results of anti-IL-13 therapies have shown mixed results in studies of adults with asthma, with some showing a reduction in asthma exacerbations [70 & ] and improved lung function [70 & ,71] , whereas others showed no improvement in exacerbation rates and or change in asthma questionnaire scores [72] . There are currently no active trials of anti-IL-13 mAb in children under 12 years. The use of anti-T H 2 biologics in current practice is limited, especially among preschool-aged children because of a lack of evidence demonstrating efficacy and safety in this population. The potential use of biologics for asthma prevention or disease-modification is an exciting area in our field and one that is likely to dramatically change practice in the coming years as further clinical trials in this age group are performed.
CONCLUSION
Although there have been many advances to our understanding of early life wheezing phenotypes, we are still left with many questions regarding how to best treat these young children. As not all children respond the same way to conventional asthma therapies, appropriate phenotyping and endotyping of wheezing children is essential to guide practitioners to the most effective therapies for management of symptoms. The bigger dilemma is the lack of proven treatment options for primary prevention of asthma. Allergen-specific immunotherapy and biologics such as anti-IgE therapy will likely be further explored for their potential for primary prevention of asthma in certain groups of young children with recurrent wheezing. 
